Document Detail


Structure-activity relationship for FDA approved drugs as inhibitors of the human sodium taurocholate cotransporting polypeptide (NTCP).
MedLine Citation:
PMID:  23339484     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The hepatic bile acid uptake transporter sodium taurocholate cotransporting polypeptide (NTCP) is less well characterized than its ileal paralog, the apical sodium dependent bile acid transporter (ASBT), in terms of drug inhibition requirements. The objectives of this study were (a) to identify FDA approved drugs that inhibit human NTCP, (b) to develop pharmacophore and Bayesian computational models for NTCP inhibition, and (c) to compare NTCP and ASBT transport inhibition requirements. A series of NTCP inhibition studies were performed using FDA approved drugs, in concert with iterative computational model development. Screening studies identified 27 drugs as novel NTCP inhibitors, including irbesartan (Ki = 11.9 μM) and ezetimibe (Ki = 25.0 μM). The common feature pharmacophore indicated that two hydrophobes and one hydrogen bond acceptor were important for inhibition of NTCP. From 72 drugs screened in vitro, a total of 31 drugs inhibited NTCP, while 51 drugs (i.e., more than half) inhibited ASBT. Hence, while there was inhibitor overlap, ASBT unexpectedly was more permissive to drug inhibition than was NTCP, and this may be related to NTCP possessing fewer pharmacophore features. Findings reflected that a combination of computational and in vitro approaches enriched the understanding of these poorly characterized transporters and yielded additional chemical probes for possible drug-transporter interaction determinations.
Authors:
Zhongqi Dong; Sean Ekins; James E Polli
Related Documents :
20201744 - Inter-laboratory variation in cerebrospinal fluid biomarkers for alzheimer's disease: u...
2672254 - Use of quinolones in chlamydial infection.
6445254 - Acceptability of drugs for male fertility regulation: a prospectus and some preliminary...
1148104 - Clinical evaluation of local anaesthetic agents.
9663634 - Operation red box: a pilot project of needle and syringe drop boxes for injection drug ...
11581524 - Progressive supranuclear palsy.
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.     Date:  2013-02-12
Journal Detail:
Title:  Molecular pharmaceutics     Volume:  10     ISSN:  1543-8392     ISO Abbreviation:  Mol. Pharm.     Publication Date:  2013 Mar 
Date Detail:
Created Date:  2013-03-04     Completed Date:  2013-09-04     Revised Date:  2014-03-06    
Medline Journal Info:
Nlm Unique ID:  101197791     Medline TA:  Mol Pharm     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1008-19     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Azetidines / chemistry,  pharmacology
Bayes Theorem
Biphenyl Compounds / chemistry,  pharmacology
Computational Biology
Humans
Organic Anion Transporters, Sodium-Dependent / antagonists & inhibitors*
Structure-Activity Relationship
Symporters / antagonists & inhibitors*
Tetrazoles / chemistry,  pharmacology
United States
United States Food and Drug Administration
Grant Support
ID/Acronym/Agency:
DK093406/DK/NIDDK NIH HHS; R21 DK093406/DK/NIDDK NIH HHS; U01FD004320-01/FD/FDA HHS
Chemical
Reg. No./Substance:
0/Azetidines; 0/Biphenyl Compounds; 0/Organic Anion Transporters, Sodium-Dependent; 0/Symporters; 0/Tetrazoles; 138402-11-6/irbesartan; 145420-23-1/sodium-bile acid cotransporter; 163222-33-1/ezetimibe
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Mechanisms for the Reactions of Group 10 Transition Metal Complexes with Metal-Group 14 Element Bond...
Next Document:  Using a model filamentous fungus to unravel mechanisms of lignocellulose deconstruction.